AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1953259 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous estradiol (E2) 17 beta and natural progesterone for 6 months
Number of subjects: 32
Study 1953259 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 32
Study 475988 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine + cimetidine
Number of subjects: 10
Study 475988 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine
Number of subjects: 10
Study 475988 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 10
Study 30772205 — intervention group
Group type: EXPERIMENTAL
Intervention: Curriculum intervention
Number of subjects: 1159
Study 30772205 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness intervention
Number of subjects: 1159
Study 30772205 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1159
Study 30772205 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based determinants
Number of subjects: 1159
Study 27893484 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic and core strengthening program (3 times a week for 6 weeks)
Number of subjects: 35
Study 27893484 — intervention group
Group type: COMPARATOR
Intervention: Normal training without additional pelvic and core strengthening (Control)
Number of subjects: 35
Study 25347936 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase group (ropivacaine 0.5% with 100 IU/ml of hyaluronidase)
Number of subjects: 48
Study 25347936 — intervention group
Group type: COMPARATOR
Intervention: Control group (ropivacaine alone)
Number of subjects: 48
Study 23777849 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin inhalation (0.48‐1000 μmol/L, 4 inhalations per dose)
Number of subjects: 58
Study 23777849 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers and asthmatic patients combined
Number of subjects: 58
Study 23777849 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin inhalation
Number of subjects: 58
Study 17533024 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 29
Study 15297192 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and irinotecan (25 mg/m² and 65 mg/m² weekly for three consecutive weeks, repeated every 28 days)
Number of subjects: 34
Study 15297192 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and irinotecan
Number of subjects: 34
Study 10795957 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 31
Study 10795957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 9341685 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke Unit
Number of subjects: 220
Study 9341685 — intervention group
Group type: COMPARATOR
Intervention: General Wards
Number of subjects: 220
Study 8519370 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 12
Study 8519370 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 12
Study 8519370 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1 mg
Number of subjects: 12
Study 3535022 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) administered twice daily
Number of subjects: 40
Study 3535022 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) administered four times daily
Number of subjects: 40
Study 31865665 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization and SACS injection
Number of subjects: 84
Study 31865665 — intervention group
Group type: COMPARATOR
Intervention: SACS injection only
Number of subjects: 84
Study 31411337 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialogue-based intervention (up to 8 individual sessions aimed at supporting coping and life skills)
Number of subjects: 322
Study 31411337 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 322
Study 30647740 — intervention group
Group type: EXPERIMENTAL
Intervention: Red light rhinophototherapy (RLRPT)
Number of subjects: 0
Study 30647740 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment only
Number of subjects: 0
Study 27685347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 12
Study 27685347 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulator guidance
Number of subjects: 12
Study 24221533 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-dependent subjects
Number of subjects: 36
Study 24221533 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 36
Study 22661489 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine‐zidovudine plus efavirenz
Number of subjects: 860
Study 22661489 — intervention group
Group type: EXPERIMENTAL
Intervention: atazanavir, emtricitabine, and didanosine‐EC
Number of subjects: 860
Study 22661489 — intervention group
Group type: EXPERIMENTAL
Intervention: emtricitabine‐tenofovir‐disoproxil fumarate plus efavirenz
Number of subjects: 860
Study 22661489 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 860
Study 19597646 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime (CFP) monotherapy
Number of subjects: 57
Study 19597646 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone plus amikacin (CFT+AK)
Number of subjects: 57
Study 17065275 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cord applications of mustard oil
Number of subjects: 17198
Study 17065275 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical applications of other potentially unclean substances
Number of subjects: 17198
Study 17065275 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact
Number of subjects: 17198
Study 17065275 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand washing by birth attendants
Number of subjects: 17198
Study 17065275 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand washing by caretakers
Number of subjects: 17198
Study 15216462 — intervention group
Group type: EXPERIMENTAL
Intervention: nelfinavir plus stavudine and lamivudine
Number of subjects: 653
Study 15216462 — intervention group
Group type: COMPARATOR
Intervention: lopinavir/ritonavir plus stavudine and lamivudine
Number of subjects: 653
Study 12512233 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/daily per oral)
Number of subjects: 40
Study 9586148 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Bed Rest (ABR)
Number of subjects: 30
Study 9586148 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigorous Bed Rest (RBR)
Number of subjects: 30
Study 9586148 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory Control Subjects (ACS)
Number of subjects: 30
Study 8580292 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive multimedia learning system
Number of subjects: 0
Study 2696483 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadine (rayon dressing with 10 per cent povidone iodine ointment)
Number of subjects: 213
Study 2696483 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadine
Number of subjects: 213
Study 2696483 — intervention group
Group type: COMPARATOR
Intervention: Bactigras (tulle gras dressing with 0.5 per cent Chlorhexidine Acetate B.P.)
Number of subjects: 213
Study 772831 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol (Trasicor)
Number of subjects: 0
Study 772831 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 31990089 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser
Number of subjects: 72
Study 31990089 — intervention group
Group type: EXPERIMENTAL
Intervention: Promestriene
Number of subjects: 72
Study 31990089 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal lubricant
Number of subjects: 72
Study 30543801 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced exercise + RTP (FE+RTP)
Number of subjects: 40
Study 30543801 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary exercise + RTP (VE+RTP)
Number of subjects: 40
Study 30543801 — intervention group
Group type: COMPARATOR
Intervention: Stroke education + RTP (EDU+RTP)
Number of subjects: 40
Study 27930813 — intervention group
Group type: EXPERIMENTAL
Intervention: Free gingival grafts (FGGs)
Number of subjects: 28
Study 27930813 — intervention group
Group type: COMPARATOR
Intervention: Oral prophylaxis only
Number of subjects: 28
Study 25759551 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnifying narrow band imaging
Number of subjects: 51
Study 25759551 — intervention group
Group type: COMPARATOR
Intervention: Lugol chromoendoscopy
Number of subjects: 51
Study 23275313 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring device (Bluetooth-enabled BP cuff with Internet-enabled hub)
Number of subjects: 43
Study 23275313 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 43
Study 20419562 — intervention group
Group type: EXPERIMENTAL
Intervention: Written self-disclosure (WSD) in addition to standard medical care (SMC)
Number of subjects: 63
Study 20419562 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (SMC) alone
Number of subjects: 63
Study 19380660 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin (25 mg) plus Pioglitazone hydrochloride (15 mg)
Number of subjects: 41
Study 19380660 — intervention group
Group type: COMPARATOR
Intervention: Acitretin (25 mg) plus placebo
Number of subjects: 41
Study 17476675 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical response or remission (defined using the Mayo score)
Number of subjects: 728
Study 17476675 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in clinical remission at week 30
Number of subjects: 728
Study 17476675 — intervention group
Group type: COMPARATOR
Intervention: Patients not in clinical remission at week 30
Number of subjects: 728
Study 17476675 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in clinical remission
Number of subjects: 728
Study 15185883 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler (TD) assessment
Number of subjects: 28
Study 15185883 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard echocardiography
Number of subjects: 28
Study 15185883 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 28
Study 15185883 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population analysis
Number of subjects: 28
Study 11352437 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 200mg oral dose of moxifloxacin
Number of subjects: 36
Study 11352437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 9044494 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated External Defibrillator (AED)
Number of subjects: 50
Study 9044494 — intervention group
Group type: COMPARATOR
Intervention: Blind Manual Defibrillation (BMD)
Number of subjects: 50
Study 9044494 — intervention group
Group type: EXPERIMENTAL
Intervention: AED
Number of subjects: 50
Study 7704289 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 25
Study 7704289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 3296721 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet treatment and one of five active drug regimens (enalapril, doxazosin, acebutolol, amlodipine, chlorthalidone)
Number of subjects: 0
Study 3296721 — intervention group
Group type: COMPARATOR
Intervention: Diet treatment alone
Number of subjects: 0
Study 29335748 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel implant (Cartiva™)
Number of subjects: 38
Study 29335748 — intervention group
Group type: COMPARATOR
Intervention: Autologous osteochondral transplantation (AOT)
Number of subjects: 38
Study 27096383 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation (PCV)
Number of subjects: 56
Study 27096383 — intervention group
Group type: COMPARATOR
Intervention: Volume-controlled ventilation (VCV)
Number of subjects: 56
Study 25004265 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (NE) infusion (0.15 mcg/kg/min)
Number of subjects: 40
Study 25004265 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion (placebo)
Number of subjects: 40
Study 22155106 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic infant formula supplemented with Lactobacillus fermentum CECT5716
Number of subjects: 0
Study 22155106 — intervention group
Group type: COMPARATOR
Intervention: Control group (same formula without probiotic)
Number of subjects: 0
Study 20444777 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (video, lecture with handout, discussion)
Number of subjects: 121
Study 20444777 — intervention group
Group type: COMPARATOR
Intervention: Control group (handout only)
Number of subjects: 121
Study 18185903 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 322
Study 18185903 — intervention group
Group type: COMPARATOR
Intervention: No Burch (control)
Number of subjects: 322
Study 18185903 — intervention group
Group type: EXPERIMENTAL
Intervention: Pessary reduction method
Number of subjects: 322
Study 18185903 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual reduction method
Number of subjects: 322
Study 18185903 — intervention group
Group type: EXPERIMENTAL
Intervention: Forceps reduction method
Number of subjects: 322
Study 18185903 — intervention group
Group type: EXPERIMENTAL
Intervention: Swab reduction method
Number of subjects: 322
Study 18185903 — intervention group
Group type: EXPERIMENTAL
Intervention: Speculum reduction method
Number of subjects: 322
Study 18185903 — intervention group
Group type: EXPERIMENTAL
Intervention: First method of prolapse reduction
Number of subjects: 322
Study 18185903 — intervention group
Group type: EXPERIMENTAL
Intervention: Second method of prolapse reduction
Number of subjects: 322
Study 16181384 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological alterations in GERD patients
Number of subjects: 135
Study 16181384 — intervention group
Group type: COMPARATOR
Intervention: Histological alterations in control group
Number of subjects: 135
Study 16181384 — intervention group
Group type: EXPERIMENTAL
Intervention: Histology in patients with erosive esophagitis
Number of subjects: 135
Study 16181384 — intervention group
Group type: EXPERIMENTAL
Intervention: Histology in patients with nonerosive reflux disease (NERD)
Number of subjects: 135
Study 16181384 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut-off value for microscopic lesions
Number of subjects: 135
Study 12527953 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate mouthwash
Number of subjects: 81
Study 12527953 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 81
Study 10688504 — intervention group
Group type: EXPERIMENTAL
Intervention: Misgav Ladach caesarean section technique
Number of subjects: 339
Study 10688504 — intervention group
Group type: COMPARATOR
Intervention: Conventional lower midline incision procedure
Number of subjects: 339
Study 8822677 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate physiotherapy (n = 9)
Number of subjects: 22
Study 8822677 — intervention group
Group type: COMPARATOR
Intervention: Control group (waited 2 months, n = 8)
Number of subjects: 22
Study 1461625 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate at a dose of 480 mg/day for 3-4 months
Number of subjects: 66
Study 1461625 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate at a dose of 160 mg/day for 3-4 months
Number of subjects: 66
Study 1461625 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (combined data for both doses)
Number of subjects: 66
Study 6428619 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (up to 48 units of highly purified porcine lente insulin)
Number of subjects: 58
Study 6428619 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 58
Study 31697453 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health program including individual oral hygiene monitoring for 2 months, awareness sessions, practical demonstration of toothbrushing and adaptive techniques with role-play.
Number of subjects: 62
Study 31697453 — intervention group
Group type: COMPARATOR
Intervention: Control group received awareness sessions and practical demonstrations without individual monitoring.
Number of subjects: 62
Study 31590104 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 49
Study 31590104 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group
Number of subjects: 49
Study 28190468 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% w/w CA-oil lotion
Number of subjects: 60
Study 28190468 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% w/w CA-oil lotion
Number of subjects: 60
Study 28190468 — intervention group
Group type: COMPARATOR
Intervention: Placebo (base-lotion)
Number of subjects: 60
Study 27259317 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity‐modulated radiation therapy (IMRT)
Number of subjects: 130
Study 27259317 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiation therapy (CRT)
Number of subjects: 130
Study 23880258 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% NaOCl (G1)
Number of subjects: 48
Study 23880258 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine (CHX) gel (G2)
Number of subjects: 48
Study 23880258 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% NaOCl + Ca(OH)2 (G3)
Number of subjects: 48
Study 23880258 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% CHX gel + Ca(OH)2 (G4)
Number of subjects: 48
Study 23880258 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-visit treatment (G3 and G4)
Number of subjects: 48
Study 23880258 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-visit treatment (G1 and G2)
Number of subjects: 48
Study 21972642 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture knife therapy
Number of subjects: 304
Study 21972642 — intervention group
Group type: COMPARATOR
Intervention: Blocking therapy
Number of subjects: 304
Study 19778736 — intervention group
Group type: EXPERIMENTAL
Intervention: Hero 642
Number of subjects: 67
Study 19778736 — intervention group
Group type: EXPERIMENTAL
Intervention: K3
Number of subjects: 67
Study 19778736 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Universal
Number of subjects: 67
Study 16915770 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetocardiography (MCG) analysis in CAD patients without MI
Number of subjects: 144
Study 16915770 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetocardiography (MCG) analysis in CAD patients with MI
Number of subjects: 144
Study 16915770 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetocardiography (MCG) analysis in CAD patients with MI and VT
Number of subjects: 144
Study 16915770 — intervention group
Group type: COMPARATOR
Intervention: Magnetocardiography (MCG) analysis in healthy subjects
Number of subjects: 144
Study 12207627 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg tibolone
Number of subjects: 2
Study 12207627 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg tibolone
Number of subjects: 2
Study 12207627 — intervention group
Group type: COMPARATOR
Intervention: 1.25 mg and 2.5 mg tibolone
Number of subjects: 2
Study 10509987 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative IABP therapy starting 2 hours (T2), 12 hours (T12), or 24 hours (T24) before the operation.
Number of subjects: 60
Study 10509987 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative IABP therapy
Number of subjects: 60
Study 10509987 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative IABP)
Number of subjects: 60
Study 8551321 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal synthesis of IgG (quantitative measurement, log IgG index)
Number of subjects: 20
Study 8551321 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative measurement (isoelectric focusing)
Number of subjects: 20
Study 8551321 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative tests for intrathecal synthesis of IgG
Number of subjects: 20
Study 2031517 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (300 mg, taken twice daily for 7 days)
Number of subjects: 40
Study 2031517 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 40
Study 2031517 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 40
Study 7198936 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy of vincristine, bleomycin, methotrexate, hydrocortisone, and 5-fluorouracil given over 24 hours every 2 to 3 weeks.
Number of subjects: 155
Study 7198936 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy before radiation therapy or surgery.
Number of subjects: 155
Study 7198936 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary adjuvant chemotherapy without cis-platinum.
Number of subjects: 155
Study 24049896 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct fluorescent antibody test
Number of subjects: 0
Study 29951769 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 19
Study 29951769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 26606886 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice from similar products (apple purees)
Number of subjects: 160
Study 26606886 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice from dissimilar products (desserts)
Number of subjects: 160
Study 26606886 — intervention group
Group type: COMPARATOR
Intervention: No choice session (one product served randomly)
Number of subjects: 160
Study 26606886 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice from pleasant products
Number of subjects: 160
Study 26606886 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice from unpleasant products
Number of subjects: 160
Study 24961816 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron
Number of subjects: 85
Study 24961816 — intervention group
Group type: EXPERIMENTAL
Intervention: pantoprazole
Number of subjects: 85
Study 24961816 — intervention group
Group type: EXPERIMENTAL
Intervention: metoclopramide
Number of subjects: 85
Study 24961816 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 85
Study 22492244 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 virus-like particle vaccine
Number of subjects: 4808
Study 22492244 — intervention group
Group type: COMPARATOR
Intervention: HAV vaccine
Number of subjects: 4808